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Background: Recently there have been efforts to derive safe, efficient processes to rule out acute coronary
syndrome (ACS) in emergency department (ED) chest pain patients. We aimed to prospectively validate an ACS
assessment pathway (the 2-Hour Accelerated Diagnostic Protocol to Assess Patients with Chest Pain Symptoms
Using Contemporary Troponins as the Only Biomarker (ADAPT) pathway) under pragmatic ED working conditions.
Methods: This prospective cohort study included patients with atraumatic chest pain in whom ACS was suspected but
who did not have clear evidence of ischaemia on ECG. Thrombolysis in myocardial infarction (TIMI) score and troponin
(TnI Ultra) were measured at ED presentation, 2 h later and according to current national recommendations. The primary
outcome of interest was the occurrence of major adverse cardiac events (MACE) including prevalent myocardial infarction
(MI) at 30 days in the group who had a TIMI score of 0 and had presentation and 2-h TnI assays <99th percentile.
Results: Eight hundred and forty patients were studied of whom 177 (21%) had a TIMI score of 0. There were no MI,
MACE or revascularization in the per protocol and intention-to-treat 2-h troponin groups (0%, 95% confidence interval
(CI) 0% to 4.5% and 0%, 95% CI 0% to 3.8%, respectively). The negative predictive value (NPV) was 100% (95% CI 95.5%
to 100%) and 100% (95% CI 96.2% to 100%), respectively.
Conclusions: A 2-h accelerated rule-out process for ED chest pain patients using electrocardiography, a TIMI score of 0
and a contemporary sensitive troponin assay accurately identifies a group at very low risk of 30-day MI or MACE.
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Chest pain is a common reason for presentation to emer-
gency departments (ED) accounting for approximately 2.4%
of all ED attendances [1]. Between 75% and 85% of patients
are ruled out for acute coronary syndrome (ACS) [2].
International guidelines for the investigation of ACS
recommend serial measurements of contemporary (non-
high sensitivity) cardiac troponin over 4 to 12 h from
symptom onset or presentation to the ED [3-6]. This can
contribute to ED overcrowding with resulting adverse
patient outcomes, including increased mortality, and
increased costs [7].* Correspondence: anne-maree.kelly@wh.org.au
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in any medium, provided the original work is pOver recent years, there have been efforts to derive safe
and efficient assessment processes - in particular
attempts to define a subgroup of patients at very low
risk and suitable for an accelerated assessment and
early discharge. One such approach has been combining
electrocardiography (ECG), thrombolysis in myocardial
infarction (TIMI) score and biomarkers to define a low-risk
group suitable for an accelerated pathway [8,9]. Such
approaches would classify 10% to 20% of chest pain presen-
tations as low risk [8,9] and have reported negative predict-
ive values exceeding 99%. To date, this approach has had
limited external validation - a retrospective validation using
data from the Advantageous Predictors of Acute Coronary
Syndromes Evaluation (APACE) trial and a study explor-
ing impact on time to discharge [10,11].
The aim of this study was to prospectively evaluate
the 2-Hour Accelerated Diagnostic Protocol to Assesss an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Troponins as the Only Biomarker (ADAPT) [9] assessment
pathway in an independent ED setting under pragmatic
ED working conditions.
Methods
This prospective cohort study was conducted in the ED
of a community teaching hospital with an annual adult
ED census of approximately 36,000 between 16 April
2012 and 3 February 2013.
Patients were screened for inclusion if they presented
with chest pain. Exclusion criteria were chest pain due
to trauma, aged <18 years, no chest pain within 24 h of
the index ED visit, chest pain lasting <10 min, no ECG
or no troponin assay performed within 24 h of index ED
visit, a clear alternative diagnosis at initial medical officer
assessment, ischaemic ECG changes at ED presentation,
haemodynamic instability, advanced terminal disease,
inability to communicate in English and declined/
unavailable for follow-up. We had data collection support
18 h a day (8 am to midnight) so patients presenting
outside these hours were also excluded.
The intervention was measurement of troponin 2 h
after the sample taken at ED presentation in addition to
the ‘routine’ samples taken at ED arrival and at least 3 to
4 h later or 6 h from symptom onset in accordance with
current National Heart Foundation (Australia) (NHF)
guidelines [5]. While the treating staff were not formally
blinded to the result of the 2-h test, it was not used for
disposition decision-making. The troponin assay used
by the laboratory was TnI-Ultra (Siemens Diagnostics,
Munich, Germany) performed on an Advia Centaur
analyzer. The test has a reported range of 0.006 to 50 μg/l.
Coefficients of variation are 10% at TnI 0.03 μg/l, 5.3% at
0.08 μg/l and 4.1% at 0.18 μg/l. The 99th percentile is
0.04 μg/l (95% confidence interval (CI) 0.03 to 0.05 μg/l)
(manufacturer's information).
Data collected included demographics, cardiac risk
factors, biomarker assay results, ED disposition, final diag-
nosis, data to calculate Global Risk Acute Coronary Events
Registry (GRACE) risk, freedom-from-events and TIMI
scores and 7- and 30-day outcomes. Seven and 30-day
outcomes were assessed by the review of medical records
and structured telephone follow-up. An independent cardi-
ologist adjudicated on the final diagnosis and outcome
for the subgroups where patients with troponin eleva-
tions on any test exceeded the 99th percentile and
were coded as non-ACS and for patients without troponin
elevations who were coded as ACS.
The primary outcome of interest was the occurrence
of major adverse cardiac events (MACE) within 30 days in
patients who had a TIMI score of 0, had presentation and
2-h TnI <99th percentile. MACE was defined as prevalent
(present at index ED visit) or incident (occurring afterinitial ED visit) myocardial infarction (MI), death, survived
cardiac arrest, cardiogenic shock, life-threatening arrhythmia,
high-degree atrioventricular block and new atrial fibrillation.
These mirror adverse events reported in similar studies. Final
diagnosis was assigned by treating cardiologists unaware of
the study. The secondary outcome of interest was MACE or
revascularization at 30 days in the same group.
Analysis was by descriptive statistics. It became clear
that there had been some variability in collection of the
2-h specimens, due largely to competing workload and
variations in laboratory time stamp practices. We chose
to analyze three groups - a per protocol group where the
laboratory time stamps for the initial and 2-h specimens
are 2 h ±15 min apart, an intention to treat group where
a specimen was time-stamped within the per protocol
definition or up to 2 h ±60 min from initial specimen
time stamp as long as a further assay at/ after the NHF
recommended interval was also taken and a group who
did not undergo a 2-h troponin assay (missed group).
The missed group underwent biomarker assays at NHF
guideline-recommended intervals or longer. Regarding
sample size, we had planned to collect data on 150 pa-
tients with a 2-h assay (giving a confidence interval ±2%);
however, the number of missed patients was higher than
anticipated and the study was stopped as data collection
support was no longer available.
The study was approved by the institutional ethics panel
and was registered with the Australia and New Zealand
Clinical Trials Registry (ACTRN12612000990820). Patients
provided verbal consent to telephone follow-up.
Results
Sample derivation is shown in Figure 1. In the 840 eligible
patients, 72 had an ACS final diagnosis (13%), 177 (21%)
had a TIMI score of 0 and 82 patients fit the criteria for
per protocol analysis with a further 15 meeting the criteria
for intention-to-treat analysis. Patient characteristics and
outcome are summarized in Table 1.
There were no MI, MACE or revascularization in the
per protocol and intention-to-treat 2-h troponin groups
(0%, 95% CI 0% to 4.5% and 0%, 95% CI 0% to 3.8%,
respectively). The negative predictive value (NPV) was
100% (95% CI 95.5% to 100%) and 100% (95% CI 96.2% to
100%), respectively.
Of note, no included TIMI-0 patient with initial
TnI <99th percentile had a biomarker rise at 2 h or
the standard testing interval.
Discussion
An accelerated ACS rule-out process integrating ECG,
score-based risk assessment and biomarker assays was first
proposed by Than et al. in the Asia-Pacific Evaluation of
Chest Pain Trial (ASPECT) study [8]. That international
study used a point-of-care multi-biomarker panel and
EXCLUSIONS
Clear alternative diagnosis at initial 
assessment 
471
No troponin test within 24 hours 408
Declined/ unavailable for followup 345
Unable to communicate in English 292
Presentation between MN and 0800
Chest pain <10 mins
238
224
No chest pain within 24 hours 155
Ischaemic ECG at presentation 91
Advanced terminal disease 37
Chest pain due to trauma 23
Haemodynamic instability 15
No ECG within 24 hours 14
Aged < 18 3
Total patients screened = 3156
Eligible patients = 840
TIMI score 0 = 177
Included in per protocol 
analysis




# Includes per protocol group
* Missed patients had biomarker analyses at standard intervals only; no 2-hour test
Figure 1 Sample derivation.
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reported a NPV of 99.1% (95% CI 97.3% to 99.8%). A
subsequent analysis of an Australasian cohort largely but
not completely overlapping with the ASPECT cohort
explored TIMI score 0, normal ECG and normal troponin I
using Beckmann Coulter AccuTnI in Australian patients
and Abbott Architect cTnI in New Zealand patientsTable 1 Patient characteristics and outcome
Parameter Per protocol
Age (median, IQR) 47 (40 to 55)
Gender (N, %) 43, 52%
Arrival by ambulance (N, %) 59, 72%
Killip class 1 (N, %) 81, 99%
History of hypertension (N, %) 17, 21%
History of diabetes (N, %) 5, 6%
History of elevated cholesterol/cholesterol treatment (N, %) 16, 20%
Smoker (N, %) 27, 33%
Family history CAD (N, %) 22, 27%
Hospital admission (N, %) 3, 4%
GRACE risk score (median, IQR) 70 (60 to 88)
GRACE freedom from events score (median, IQR) 323 (312 to 3
MACE at 7 days (N, %, 95% CI) 0, 0%, 0% to 4
MACE at 30 days (N, %, 95% CI) 0, 0%, 0% to 4
MACE or revascularization at 30 days (N, %, 95% CI) 0, 0%, 0% to 4
ITT, intention to treat; IQR, interquartile range; CAD, coronary artery disease; GRACE
events. aIncludes per protocol group; bstandard biomarker interval only, no 2-h spe(the ADAPT study) [9]. It reported a NPV of 99.7%
(95% CI 98.6% to 100%). A further analysis using
ADAPT study patients, TIMI 0 and a high-sensitivity
troponin assay (Abbott Architect high-sensitivity TnI)
reported a NPV of 100% (95% CI 98.8% to 100%) [12].
While the NPVs are impressive, these analyses use data
from significantly overlapping cohorts and as such aregroup (N = 82) ITT group (N = 97)a Missed patientsb (N = 80)
48 (40 to 55) 49 (41 to 56)
53, 55% 36, 46%
70, 72% 62, 79%
95, 98% 76, 96%
20, 21% 16, 20%
5, 5% 2, 3%
18, 19% 21, 27%
32, 33% 16, 20%
28, 29% 22, 28%
5, 5% 6, 8%
70 (59 to 88) 77 (60 to 89)
33) 323 (311 to 333) 325 (312 to 336)
.5% 0, 0%, 0% to 3.8% 0, 0%, 0% to 4.6%
.5% 0, 0%, 0% to 3.8% 0, 0%, 0% to 4.6%
.5% 0, 0%, 0% to 3.8% 1, 1.3%, 0.2% to 6.8%
, Global Risk Acute Coronary Events Registry; MACE, major adverse cardiac
cimen.
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performed on the APACE study cohort and reported a
NPV of 100% (98.4% to 100%) [12]. In a study exploring
the impact of the accelerated pathway on discharge within
6 h, Than reported a NPV of 98.9% (95% CI 94.2% to
99.8%) [13].
Our prospective study adds to the body of evidence
that patients with a TIMI score of 0 can have ACS ruled
out by an accelerated 2-h rule-out process using a con-
temporary sensitive troponin assay. Pooled with the re-
sults of other studies using the accelerated pathway and
sensitive (but non-high sensitive) troponin [9,11] yields
a NPV for MACE at 30 days of 99.7% (95% CI 98.7% to
99.9%). This low level of risk is likely to be acceptable
to patients and clinicians. In a previous study, when
implementation was studied, the accelerated process
resulted in a higher proportion of patients being safely
discharged within 6 h of ED presentation (19.3% vs. 11%)
[11]. A change of this magnitude if replicated outside of
trial conditions would result in clinical meaningful
improvements in ED capacity and reduce overcrowding.
Other approaches to accelerated ACS rule out are
also being developed. These include modifying the
process used in this study to include patients with TIMI
score ≤1 and using a high-sensitivity troponin assay
[12]. That approach reports NPV in excess of 99% and
would classify approximately 40% of patients as low risk
and suitable for the accelerated assessment pathway but
waits external validation. Other approaches to clinical risk
assessment such as the EDACS score [13], the HEART
score [14] and the North American Chest pain rule [15]
have been developed, and their use in combination with
ECG and biomarkers is under investigation. Yet another
approach being explored is the use of changes in troponin
level over time (delta troponin) [16]. Which approach or
approaches prove to be practical, reproducible, safe and
effective and whether any are superior to the approach
studied here will evolve over the next few years.
In this study, we found that no included patients with a
TIMI score of 0 and initial TnI <99th percentile went on
to have a significant troponin rise or MI diagnosis yielding
a NPV of 100% (95% CI 97.9% to 100%). This study was
not designed or powered to test this hypothesis so it
would be inappropriate to draw conclusions from this
result. That said, it may be worthy of further study.
This study has some limitations that should be consid-
ered when interpreting its results. It was a single-centre
study; so, it may not be generalizable to other sites,
although its results are consistent with those of other
centres. The sample size is less than what was planned
resulting in wider than desired confidence intervals. The
study was conducted under pragmatic ED conditions so
samples for troponin assay were not always collected at
the exact planned intervals; however, this is the reality ofED clinical practice. While patients were identified pro-
spectively, some data regarding risk factors, etc. were
collected retrospectively so may have been subject to
documentation error.
Conclusions
A 2-h accelerated rule-out process for ED chest pain
patients using ECG, TIMI score of 0 and a contemporary
sensitive troponin assay accurately identifies a group at low
risk of 30-day MI or MACE.
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